CDC42EP2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09464(CDC42EP2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09464(CDC42EP2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The CDC42EP2 antibody is a valuable tool for studying the CDC42 effector protein 2 (CDC42EP2), a member of the CDC42 effector proteins (EPs) family. CDC42EP2. also known as BORG2 or CEP2. interacts with the Rho GTPase CDC42 to regulate cytoskeletal reorganization, cell polarity, and morphogenesis. It contains a conserved BORG (Binder of Rho GTPases) domain, enabling binding to CDC42 and other GTPases like RAC1. thereby modulating actin dynamics and cell adhesion.

CDC42EP2 is implicated in diverse cellular processes, including cell migration, inflammatory responses, and epithelial-mesenchymal transition (EMT). Dysregulation of CDC42EP2 has been linked to pathologies such as cancer metastasis, neurological disorders, and immune dysfunction. Antibodies targeting CDC42EP2 are typically generated using recombinant protein fragments or peptide immunogens, often in rabbit or mouse hosts. They enable applications like Western blotting, immunofluorescence, and immunohistochemistry to localize and quantify CDC42EP2 expression in tissues or cultured cells.

These antibodies are crucial for investigating CDC42EP2's role in signaling pathways, its interplay with cytoskeletal regulators, and its potential as a biomarker or therapeutic target. Validation often includes knockout cell lines or tissue-specific expression analyses to confirm specificity. Research using CDC42EP2 antibodies has advanced understanding of cellular motility, tissue remodeling, and disease mechanisms, particularly in cancer and inflammatory conditions.